Fluorometric imaging plate reader (FLIPR) membrane potential dyes (FMP-Red-Dye and FMP-Blue-Dye) were evaluated for the detection of compounds acting either as positive allosteric modulators or agonists on the GABA A receptor (GABA A R). A stable HEK293 cell line with constitutive expression of the rat GABA A R α1, β2, and γ2 genes was used to establish a functional high-throughput screening (HTS) assay based on measurement of the membrane potential change in living cells. The assay was validated with the FLIPR technology for identification of agonists and positive allosteric modulators using GABA and diazepam as model compounds. The FMP-Red-Dye showed better performance than the FMP-Blue-Dye, and the effects induced by GABA and diazepam were comparable to electrophysiology data. Subsequently, the assay was also validated with an ultra-HTS approach known as microarrayed compound screening (μARCS). The LOPAC library was used in a test screen for an initial assessment of the technology. Finally, the FLIPR and μARCS technologies were tested with a larger screening campaign. A focused library of 3520 putative positive modulators was tested with the FLIPR assay, and a diverse subset of 84,480 compounds was selected for screening with the μARCS technology. All hits were subjected to verification using the FLIPR technology, and confirmed hits were subsequently evaluated by EC50 determination. Finally, selected hits were further confirmed with electrophysiology testing. (Journal of Biomolecular Screening 2008:218-228) 
INTRODUCTION

I
ON CHANNELS ARE CRITICAL TO THE FUNCTION of excitable and nonexcitable cells and represent a large and diverse group of drug targets for future treatment of clinical indications, including Alzheimer's disease, epilepsy, heart disease, neuromuscular disease, cancer, diabetes, and inflammatory diseases. 1 Modulation of ion channel function is a well-validated approach in drug therapy. Approximately 15% of the world's current 100 top-selling drugs target ion channels, 2 implicated in the conditions of anxiety, sleep disorders, epilepsy, hypertension, diabetes, and chronic pain.
GABA A receptors belong to the family of ligand-gated ion channels, which includes the nicotinic acetylcholine receptor family, the glycine receptor family, and the serotonine type-3 receptor. GABA A receptors are the major inhibitory neuronal ion channels in the mammalian brain, and modulation of this ion channel group has been successfully used as anesthetics and for the treatment of anxiety, epilepsy, sleep disorders, and psychosis. 3 Most GABA A receptors are thought to be pentameric assemblies containing α, β, and γ subunits or α, β, and δ subunits. The 5 subunits are arranged around a central Cl --selective channel, and the major receptor subtype in the brain consists of α1, β2, and γ2 subunits. To date, 16 different GABA A subunit isoforms have been identified (excluding the GABA C receptor subunits ρ1-ρ3), and a large number of functional hetero pentamers have been described. [3] [4] [5] Several studies with animal models have revealed distinct pharmacological effects that are specifically mediated by different receptor isoforms. 6 These findings have spurred a race for the development of novel ion channel modulators showing specificity restricted to distinct isoforms and thus, it is hoped, circumventing well-known side effects of current GABA A R drugs, such as sedation, ataxia, cognitive impairment, amnesia, and potential for abuse.
Ion channel drug discovery has been difficult to address due to the lack of suitable high-throughput screening (HTS) methodologies. State-of-the-art whole-cell patch-clamp and planar patchclamp technologies are not easily amenable to HTS evaluation of large compound libraries. Recently, however, fluorescence-based assays have been described, [10] [11] [12] [13] one using a fluorometric imaging plate reader (FLIPR) membrane potential dye (FMP-Dye) that partitions across the intra-and extracellular plasma membrane compartments in a voltage-dependent manner. 14, 15 Upon depolarization of the cells, the dye movement into the cell and subsequent binding to intracellular hydrophobic sites induces an increase of the fluorescence signal. Conversely, membrane hyperpolarization triggers dye extrusion from the cell and decreases fluorescence.
The purpose of this study was to determine the suitability of FMP-Dyes (FMP-Red and FMP-Blue) for HTS, using GABA A Rexpressing cells as a model system. The assay developed was initially validated on the FLIPR and the microarrayed compound screening (μARCS) technology, an ultra-HTS format that uses thin agarose layers to immobilize FMP-Dye loaded cells for exposure on a high-density array of spotted compounds. In this report, we demonstrate that the approach is robust, yielding a number of GABA A R modulators. All hits were verified with the FLIPR technology, and the most promising of the verified hits were also confirmed by electrophysiology.
MATERIALS AND METHODS
Reagents
All cell culture reagents, including Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS), penicillin, streptomycin, geneticin, and 0.5% trypsin/EDTA, were purchased from Invitrogen (Carlsbad, CA). FLIPR Membrane Potential Assay Kits Blue-Dye (product #R8042) and Red-Dye (product #R8126) were purchased from Molecular Devices Corporation (Sunnyvale, CA). Black poly-D-lysine-coated 384-well clearbottom microplates and tissue culture flasks (175 cm 2 ) were purchased from Becton Dickinson Labware (Franklin Lakes, NJ). The LOPAC library was from Sigma (St. Louis, MO). Low Melt Temperature Agarose (product #50221) was from BioWhittaker Molecular Applications (Walkersville, MA).
Cell culture
The HEK293 wt cell line was purchased from the ATCC repository (LGC Promochem Sarl, France) and was transfected with the rat α1β2γ2 GABA A receptor subtype using calcium phosphate-mediated transfection, according to the standard protocol provided by the manufacturer (Invitrogen, K2780-01). Stable cell lines were selected for neomycin resistance using 500 μg/mL geneticin, and pure subclones were selected with limiting dilutions. The cells were cultured and maintained in DMEM and nutrient F-12 mixture (DMEM/F-12 with GlutaMax I, Invitrogen). The medium was supplemented with 10% FCS, 100 U/mL penicillin, and 100 U/mL streptomycin, and 500 μg/mL of geneticin was added for the GABA A R-HEK cells only. Cultures were maintained in a humidified Heraeus BB6220 incubator (Kendro Laboratory Products, Asheville, NC) at 37 °C in an atmosphere with 5% CO 2 in air.
Selection and handling of test samples
A focused library of putative positive allosteric modulators was selected from a total of approximately 700,000 compounds of the Biofocus DPI inventory. A list of 62 structures from the MDDR library (MDL Drug Data Reports, MDL Information Services, San Leandro, CA) that have been annotated actives on different GABA A receptors was compiled. The Biofocus DPI inventory was searched for compounds with more than 75% similarity to any of the compounds in the list. MACCS key and Tanimoto coefficient were used as similarity metrics. This resulted in 36,312 compounds, which corresponded to 45 clusters. The selection of 3520 compounds from that list was done by selection of highest ranked compounds in each cluster, up until the number of compounds to be selected was reached. In contrast to simple sorting of the results by the similarity coefficients, this method ensured a balanced representation of the clusters in the final selection.
Stock solutions of the compounds (3.3 mg/mL in 100% DMSO) were stored at 4 °C in sealed 384-well polypropylene microplates. For screening, 1 μL was transferred into compound plates that were sealed and stored at 4 °C.
Preparation of ChemCards and compound selection for μ μARCS screen
Compounds were diluted in DMSO to an average concentration of 2 mM. A modified Constellation 1200 spotter (Gilson, Middleton, WI) was used for spotting of the 20-nL solution of each compound on ChemCards. Duplicate spots were applied following an optimized algorithm to ensure that compounds, which lay in close proximity, had their duplicate spots located at minimal distances to allow reliable hit identification. Fresh prepared ChemCards were left at room temperature under nitrogen flow for approximately 4 h to allow complete evaporation of the DMSO, leaving the compounds as dry films. ChemCards were sealed in vacuum bags for long-term storage at room temperature. For this project, 20 ChemCards were selected from a total of 400 ChemCards in the Biofocus DPI inventory using the Maxiverse software (Biofocus DPI AG, Allschwil, Switzerland) that maximizes the chemical diversity for a given number of screening plates.
FLIPR assay
On day 1, cells from 80% confluent 175-cm 2 flasks were harvested with 0.5% trypsin/EDTA, and 10,000 cells per well were seeded into poly-D-lysine-coated 384-well plates with a Multidrop Micro liquid dispenser (Titertek Instruments, Huntsville, AL), applying a volume of 40 μL per well. Assay plate preparation was followed by incubation at 37 °C under an atmosphere of 5% CO 2 for approximately 24 h.
On day 2, an EMBLA 384 washer (Skatron, Lier, Norway) was used to wash the cells 3 times with 70 μl of assay buffer (NaCl 137 mM, KCl 4 mM, CaCl 2 1.8 mM, MgCl 2 1 mM, HEPES 10 mM [pH 7.4], glucose 10 mM, pluronic-F127 0.02%), leaving a rest volume of 25 μL. An additional 25 μL of FMP-Dye was applied as suggested by the manufacturer, but a 5-fold reduced concentration was used. The FMP-Dye was added with a multidrop liquid dispenser followed by incubation at 37 °C for 30 to 45 min prior to measurement with the FLIPR.
Immediately before use, all compound plates were diluted with assay buffer to a final concentration of approximately 120 μM. Compound addition in the FLIPR was done with a volume of 10 μL, reaching a final compound concentration of about 20 μM. For detection of positive allosteric modulators, the cells were incubated with the compounds for 4.5 min followed by addition of GABA at a concentration corresponding to approximately EC 10 , which was between 1 and 2 μM for the FMP-RedDye, depending on the cell batch. The same protocol without the second addition of GABA was used to test agonists.
Processing of FLIPR data
For all FLIPR experiments, the baseline (B1) was monitored for 1 min prior to addition of the compound. The background signal was reduced by about 10% due to a dilution effect upon compound addition. Therefore, a second baseline (B2) was recorded for 1 min before addition of GABA (see Fig. 3A ). For normalization of the response, the maximum signal, measured as arbitrary fluorescence units after GABA addition, was divided by the second baseline B2, typically resulting in values between 1 and 1.8, the latter for strong positive modulators. The normalized data were converted into relative activities Ar(%) using 0% and 100% controls, which were included on every assay plate. For 0% controls, GABA was added at a concentration corresponding to EC 10 , and 100% controls received a saturating GABA concentration, which was 200 μM for the FMP-Red-Dye.
EC 50 values were determined from dose-response curves for selected hit compounds at 8 distinct concentrations in duplicate. A 4-parametric sigmoidal activity curve was used for fitting each data set, according to the standard procedure. The DataFactory software (Biofocus DPI AG, Allschwil, Switzerland) was used for all calculations. To evaluate the quality of the experimental data, we routinely determined the coefficient of variation (CV) for 0% control and 100% control wells, the signal-to-background ratio (S/B), and the Z′ factor 16 for each assay plate.
μ μARCS assays
The μARCS technology is an ultra-HTS assay format applying a thin agarose layer to immobilize cells expressing the gene of interest. For this study, the GABA A R-HEK cells were cast into an agarose gel in the presence of the FMP-Dye. 17 Subsequently, the agarose gel was brought into contact with an array of compounds spotted onto a ChemCard. A ChemCard has the size of a standard microplate, but a total of 4224 compounds can be spotted in duplicate. Upon diffusion of compounds into the gel, the compounds interact with the cells, leading to local changes in the membrane potential due to GABA A R interaction. These membrane potential changes can be visualized as distinct spots using a CCD-based fluorescence reader. Primary hit finding is supported by a proprietary software tool (ChemCard Express), which has been designed for automatic recognition and evaluation of duplicate spots. This technology allows screening of >100,000 compounds per day. The gels for the μARCS experiments were prepared with a specially designed Gel Caster™ (Discovery Partners Systems) using a final concentration of 1.1% Low Melt Temperature Agarose (BioWhittaker Molecular Applications). In brief, a 1/1 mixture of Hanks's balanced salt solution (HBSS) supplemented with 20 mM HEPES (pH 7.4) and assay buffer without glucose and pluronic (NaCl 137 mM, KCl 4 mM, CaCl 2 1.8 mM, MgCl 2 1 mM, HEPES 10 mM [pH 7.4]) was mixed with 2.2% of agarose and brought to the boil, followed by controlled cooling to 37 °C with the Gel Caster™ and subsequent addition of prewarmed glucose to reach a concentration of 5 mM. In parallel, the FMP-Dye solution was prepared, and a concentration 2.5 times lower than recommended by the manufacturer was used with a 1/1 mixture of HBSS supplemented with 20 mM HEPES (pH 7.4) and assay buffer without pluronic. The FMP-Dye solution was brought to 37 °C on the Gel Caster™ and used for resuspension of harvested cells at a concentration of 2 × 10 6 cells/mL. Thereafter, 5 mL of the cell solution was added slowly to 5 mL of the agarose solution while stirring at 37 °C. The gel was poured with a syringe between 2 plastic sheets held at a distance of 0.7 mm by a specially designed spacer. The gel was cooled to room temperature followed by incubation for 30 min at 37 °C in a cell incubator. Subsequently, the gel was exposed on a ChemCard for 5 min, then imaged with the ViewLux Reader (PerkinElmer, Waltham, MA), using an excitation filter with the specifications 525/20 nm and an emission filter with the specifications 598/25. For identification of positive modulators, the primary gel was overlaid with a second gel that did not contain cells but was supplemented with 30 μM GABA. Putative positive modulators showed no signal on the first image but produced a clear signal after application of the GABA gel.
Processing of μ μARCS data
The ChemCard Express software was used for processing each image and for identifying location, size, and shape of spots. The locations of hit spots were corroborated using known alignment dots (20 nL black ink in DMSO) that were placed in specific locations along the edges of the card. The software resolved ambiguity of hit identification by monitoring potential duplicate hit spots for proper alignment with duplicate compound dots. In addition, the similarity of potential duplicate spots was considered to exclude artifacts and make accurate selections.
Electrophysiology
Cells were ready for electrophysiological experiments 24 to 48 h following subculturing into 35-mm culture dishes. After formation of a giga-ohm seal between the patch electrodes and individual cells (pipette resistance range: 2.0-7.0 MΩ; seal resistance: >410 MΩ), the cell membrane across the pipette tip was ruptured to ensure electrical access to the cell interior (whole-cell patch configuration). The cells were voltageclamped at a holding potential of -80 mV, and as soon as a stable seal could be established, GABA inward currents were measured upon addition of 1 to 3 μM GABA (corresponding tõ EC 10 ) to patch-clamped cells. Once control recordings were accomplished, cells were perfused with a coapplication of 1 to 3 μM GABA and the test substances (modulators). The degree of current modulation was calculated as a percentage of the control response. For measurement of agonistic activity, the test substances were applied without the neurotransmitter GABA. Fast drug application was accomplished by means of the Rapid Solution Changer (Bio-Logic, Claix, France). The protocol was established with short exposure times to avoid receptor desensitization. The bath solution for electrophysiological experiments consisted of NaCl (137 mM), KCl (4 mM), CaCl 2 (1.8 mM), MgCl 2 (1 mM), HEPES (10 mM), and D-glucose (10 mM). The pH of the bath solution was adjusted to 7.4 using NaOH. The pipette solution consisted of KCl (130 mM), MgCl 2 (1 mM), Mg-ATP (5 mM), HEPES (10 mM), and EGTA (5 mM). The pH of the pipette solution was adjusted to 7.2 using KOH. Cells were continuously perfused with the bath solution at approximately 1 mL/min (gravity driven). All solutions applied to cells, including the pipette solution, were maintained at room temperature (25 °C).
Liquid chromatography/mass spectrometry analysis
Compounds were automatically injected and resolved on a Max-RP column (50 × 2 mm, 80 Å, 4 μm; Phenomenex, Torrance, CA) using a 5% to 90% gradient of acetonitrile/0.05% formic acid versus water/0.05% formic acid. A UV-detector (210 nm) was used for purity determination. The API 150ex Single Quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) was coupled directly behind the UV detector without previous flow splitting. Standard methodology was applied for mass determination. Data acquisition and processing were done with Analyst™ software (Applied Biosystems).
RESULTS AND DISCUSSION
Activation of GABA A R-HEK cells with GABA
To investigate the properties of the FMP-Dyes, we used a HEK293 cell line constitutively expressing the rat GABA A R α1, β2, and γ2 genes (GABA A R-HEK cells). The mature rat proteins share very high amino acid identity (approximately 99%) with the human orthologs, and hence the probability is very high that potential drug candidates active on the rat receptor will exert similar effects on the human homolog. Therefore, it was assumed that the assay described here would be suitable for preclinic drug discovery efforts.
Initially, the FMP-Dyes were assessed for detection of signals induced by exposure of the cells to various concentrations of GABA. It was found that 10,000 cells per well resulted in Fig. 1 and Table 1 ). The FMP-Red and FMP-Blue-Dyes reached maximal signals with final GABA concentrations of 100 to 200 μM and 1.5 mM, respectively. The kinetics of the recorded fluorescence traces were very similar, but a moderate increase of the S/B ratio was detected with the FMP-Red-Dye ( Fig. 2A) . Using whole-cell patch clamping, the maximal signal was reached at a GABA concentration of about 100 μM ( Figs. 1, 2B) , similar to the result obtained with the FMP-RedDye. For negative controls, either GABA A R-HEK cells were exposed to buffer only or wt-HEK cells were exposed to various GABA concentrations. All control experiments resulted in a stable baseline as expected, and for simplicity, only a few controls are shown in the figures.
Finally, dose response was measured with the μARCS technology. The experiment was conducted with the FMP-Red and FMP-Blue-Dyes, and a clear dose response was detected for both procedures (Fig. 2C) . Automatic spot finding was performed with the ChemCard Express software, providing a quantification of the signals by determination of spot radius and average intensity. These parameters were used to calculate "Spot Area × Intensity," and EC 50 values were calculated to 41 and 48 pmol of spotted compound for the FMP-Red-Dye and the FMP-BlueDye, respectively. The corresponding Hill slopes were 1.4 and 1.8, respectively (Fig. 2D) . The FMP-Red-Dye showed significantly lower EC 50 values in the plate-based assay than the FMPBlue-Dye. Strikingly, no significant difference was observed with the μARCS technology. We can only speculate at this stage how the different quenching dyes (red vs. blue) or the gel material could change the performance of the assay. Further investigation of this is needed.
Effects of GABA A R modulators
Diazepam is a central nervous system depressant and anxiolytic, and its main target is the GABA A R. Diazepam is a positive allosteric modulator, which alters GABA binding at the GABA A R in an allosteric fashion but does not directly activate the receptor. 18 We used diazepam for validation of the GABA A R-HEK cells with the FMP-Dyes. Positive modulating effects of diazepam were tested with the FMP-Dyes by exposure of GABA A R-HEK cells to 20 μM diazepam prior to addition of GABA at a low concentration corresponding to approximately EC 10 (Fig. 3A) . Diazepam clearly enhanced the GABA signal from 19% to 47% relative activity (enhancement = 147.4%), as determined with the FMPRed-Dye. Comparable results were generated with the FMPBlue-Dye (data not shown). Overall, the observed effects were similar to electrophysiology, in which a signal induced with 2 μM GABA was enhanced by 201.7% with application of 1 μM diazepam (Fig. 3B) . The effects of diazepam could only be observed in the FLIPR experiments at significantly higher concentrations in comparison with electrophysiology. This effect is most likely due to adsorption of diazepam (with a logD of approximately 2.8 at pH 7.4) onto plastic materials (e.g., microplates and pipette tips). The used materials and workflow between the 2 methods were very different; in particular, with electrophysiology, a microfluidic device was used to directly apply the compound to the cell. Therefore, exposure to large plastic surfaces as it occurs in microplates was not possible. EC 50 values for GABA dose response were also calculated in the presence of different diazepam concentrations. A maximal shift from 10.5 to 3.1 μM (factor 3.4) was detected with the FMP-Red-Dye applying a diazepam concentration of 4.0 μM (Fig. 3C) . For the FMP-BlueDye, the EC 50 values were shifted from 49.6 to 10.1 μM (factor 4.9), and the maximum shift was reached at 13.3 μM of diazepam (data not shown).
Picrotoxin (PTX) is an activation-dependent GABA A R blocker that is thought to mediate blocking after a conformational change initiated by GABA binding to the receptor. 19 PTXmediated inhibition of GABA A R activation by GABA was successfully detected with both the FMP-Red and FMP-Blue-Dyes. Corresponding IC 50 values were 3.45 and 14.89 μM for FMP-Red and FMP-Blue-Dyes, respectively ( Table 1) , and these outcomes were comparable to results obtained with electrophysiology, where IC 50 values ranged between 5 and 10 μM. 20 Therefore, both the red and blue membrane potential dyes were suitable for detection of GABA-mediated depolarization of the GABA A R-HEK cell line. Channel modulation with PTX and diazepam could be detected, and IC 50 /EC 50 values were successfully calculated. However, results obtained with the FMP-Red-Dye correlated better with electrophysiology data.
μ μARCS validation with the LOPAC library
The entire LOPAC library (640 compounds) was screened using the μARCS technology (Fig. 4) . All compounds were dissolved in DMSO at concentrations of 2 and 0.2 mM. Both concentrations were spotted on ChemCards in duplicate applying 20 nL, allowing simultaneous screening at 2 different concentrations. The 2 FMP-Dyes led to very similar results. The gel with the FMP-Red-Dye was incubated for a slightly longer period, resulting in larger spots due to prolonged compound diffusion. In this experiment, no signal could be observed for compounds 2 and 6 ( Fig. 4B) at low concentration (spots 2c/d and 6c/d). However, 7 compounds of the LOPAC library have been annotated as GABA A R agonists, including GABA and muscimol, which were detected at high and low spotting concentrations (Fig. 4 , compounds 1 and 2, respectively). In addition, isoguvacine, thiomuscimol, and piperidine-4-sulphonic acid were detected at the high concentrations (Fig. 4, compounds 3, 4 , and 5, respectively). 4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridine-3-ol hydrochloride (THIP) and isonipecotic acid were not detected, but subsequent quality control by liquid chromatography/mass spectrometry (LC/MS) revealed very low purity of these compounds, thus explaining the absence of signals. In summary, 5 of 7 annotated agonists were identified, and the missing 2 agonists were shown to be of very low purity. This result validates the μARCS technology as a powerful tool for the identification of GABA A R agonists. Only 1 compound, ibotenic acid (Fig. 4, compound 6 ), was unexpectedly identified as a hit at low and high concentrations. This compound is known to be converted to the GABA A R agonist muscimol through decarboxylation. 21 
LC/MS failed to confirm
Using FMP-Dyes for HTS with the GABA A Receptor the presence of either ibotenic acid or muscimol. Instead, several larger masses were detected, indicating a more complex combination of dimerization and degradation. It is likely that a muscimol derivative may have been generated through this process, leading to a very strong signal in the μARCS assay.
FLIPR screen for positive modulators
With the FLIPR, a final screening concentration of approximately 20 μM was used. For identification of positive modulators, GABA A R activation was triggered by the addition of GABA at a concentration of 1 μM, corresponding to approximately EC 10 . For hit identification, the maxima detected after GABA addition were divided by the average of the baseline measured immediately before GABA addition. These ratios were compared with 100% and 0% controls, which received 200 μM and 1 μM GABA, respectively. The relative activity was calculated for each compound, and the activity cutoff was set to ≥20%. For counterscreening, all compounds were tested in parallel with wt-HEK cells. In this case, no signal could be induced with GABA; therefore, the baseline was set as 100%, and deviation from the baseline was monitored. This procedure allowed elimination of compounds, which induce cell depolarization through a nonspecific mechanism or compounds showing fluorescence. For the counterscreen, the cutoff activity was set to ≤110%. At this stage, a total of 177 putative positive modulators were identified, and all compounds were subjected to quality control with LC/MS analysis. A total of 124 compounds with purity ≥70% were selected for further analysis with EC 50 testing. EC 50 determination was carried out in duplicate using 8 compound concentrations starting from 30 μM plus 7 serial 1:3 dilutions. As described for the primary screen, the cells were first exposed to the compounds prior to addition of GABA at a concentration corresponding to approximately EC 10 . In parallel, the effects of all compounds on the EC 50 value of GABA were determined. For this purpose, the cells were exposed to 30 μM compound prior to addition of GABA at 8 different concentrations ranging from 200 μM to 91 nM (1:3 serial dilution). The resulting EC 50 values were called "EC 50 _Shift" because a lowered, and hence shifted, value was expected for compounds with positive modulating activities. Ranking of the EC 50 values and "EC 50 _Shift" values was combined with visual inspection of the fluorescence traces, resulting in the prioritization of 65 compounds, which were then tested for inhibition with picrotoxin. For this procedure, the cells were exposed to 100 μM picrotoxin prior to the addition of the 30-μM compound, followed by signal induction with GABA at EC 10 . The data were converted into relative activities in comparison with 100% and 0% controls, and the ΔPTX values were calculated by subtraction of the PTX inhibited signal from the noninhibited signal. The final 65 compounds were grouped into 31 clusters, using a combination of MACCS and 2D topological keys and applying a Tanimoto similarity threshold of 0.7. Within the clusters, the compounds were ranked after maximal ΔPTX, and the top compound from each cluster was selected for electrophysiology studies. At this stage, 2 clusters that lacked PTX-mediated inhibition and 7 clusters for which compound supply was not sufficient were excluded, leaving a final selection of 22 compounds. Detailed data for the 5 most potent positive modulators are given in Table 2 (compounds 1-5). selected as putative positive modulators. All compounds were tested in the FLIPR using the same procedure as outlined in the preceding section, but GABA addition was omitted for the agonists. The cutoff was set at ≥35% for the agonists and at ≥20% for the positive modulators with the GABA A R-HEK cells and at ≤110% for the counterscreen with wt-HEK cells. At this stage, a total of 120 putative agonists and 6 putative positive modulators were identified, which were reduced to 92 and 4 compounds, respectively, following quality control with LC/MS analysis. Subsequent experiments were performed with all compounds for determination of EC 50 values. The 4 remaining positive modulators were included in the group described in the section above, and in this case, "EC 50 _Shift" values also were determined. Ranking of the EC 50 values was combined with visual inspection of the fluorescence traces for further prioritization of 44 putative agonists and 2 putative positive modulators, which were then subjected to testing of inhibition with picrotoxin as outlined above. The data were converted into relative activities in comparison with 100% and 0% controls, the agonists were ranked by descending ΔPTX values, and 6 compounds were tested with electrophysiology. All relevant data for the 4 most potent agonists are summarized in Table 3 . In addition, the 2 positive modulators were tested with electrophysiology, and all relevant data for 1 compound are given in Table 2 (compound 6). Figure 5A , B depicts an example of a μARCS gel, containing 2 agonists, which were confirmed with the FLIPR follow-up testing (Fig. 5C) . Approximately 10% of the ChemCard spots were hits that could be confirmed by FLIPR testing.
CONCLUSIONS
In this study, we used the FMP-Red and FMP-Blue-Dyes to establish ion channel screening with a GABA A receptorexpressing cell line, in both 384-well plate format and in the μARCS format. Both dyes were suitable for detection of The potential actives were tested on the fluorometric imaging plate reader (FLIPR) using GABA A R-HEK cells. EC 50 values are given in μM. ΔPTX values were calculated as described in Table 2 . Finally, 8 potential agonists were identified, of which 6 were subjected to electrophysiology testing, leading to 4 confirmed hits. PTX, picrotoxin; EP, electrophysiology. a. Relative activities compared to GABA at EC 10 = 100%; average of 3 to 5 experiments.
data. Therefore, only this dye was used for the screening of a focused library of potential positive allosteric GABA A R modulators in the 384-well format. Seventeen compounds could be confirmed with electrophysiology, all showing enhancement of the EC 10 signal by at least 30%. Only data for the 5 most potent compounds are shown ( Table 2 ). In addition, the FMP-RedDye was applied for the μARCS screening with a diverse selection of 84,480 compounds. With this procedure, 6 agonists and 2 positive modulators were identified, and 4 and 2 were also confirmed with electrophysiology, respectively. Data for the agonists are given in Table 3 , and 1 of the positive modulators was included in Table 2 (compound 6). The μARCS technology allows primary screening of large compound libraries at a cost reduction of up to 90% in comparison with the commonly used 384-well formats. This method allows very fast generation of primary hits for subsequent verification with the FLIPR technology or with voltage/ion probe reader (VIPR), atomic absorption spectroscopy (AAS), voltage sensor probe (VSP), and automated planar patch clamping.
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These technologies can also be used for in vitro pharmacology, which will include studies with known inhibitors and specificity testing against other receptors. Due to the efficiency of μARCS technology, bottlenecks are likely to occur during follow-up procedures; therefore, the use of "differential" μARCS screening run in parallel with different receptors might be envisaged for future applications. In the case of GABA A receptors, synchronous testing of various subtypes containing any of the α1, α2, α3, or α5 subunits would allow identification of specific compounds at a very early stage. Subsequently, the FLIPR technology could be applied for testing of focused libraries generated during medicinal chemistry programs, leading to structure-activity relationship (SAR) studies. However, for final and more detailed mechanistic studies of channel modulation (e.g., use-dependent modulation), electrophysiology should be applied as the current gold standard.
Only limited structural information is available for ion channels and other large multisubunit targets such as G-proteincoupled receptors, transporter proteins (transmembrane pumps), but also complex enzymes such as γ-secretase. Therefore, in silico-based rationalization for focused compound selection still remains a challenge. The approach and technology described here represents an attractive option for the screening of such drug targets using large compound libraries with >1Mio compounds.
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